Compare KB Financial Group, Inc. (KB) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Repligen Corporation Common Stock — how do they compare? KB Financial Group, Inc. trades at $115.32 (market cap $42.72B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: KB Financial Group, Inc. is far larger — about 3.8× Repligen Corporation Common Stock's market cap, and KB Financial Group, Inc. pays a 2.73% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Repligen Corporation Common Stock for 0 Days on average.
| KB | RGEN | |
|---|---|---|
Market Cap | $42.72B | $11.14B |
Volume | 268,131 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $132.88 | $194.57 |
52-Week Low | $80.15 | $102.87 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $214.27T | $11.02B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $117.00, down 4.08% on the day, with bearish technical signals from moving averages. Fundamentally, the company shows strong profitability with 28.09% net income margin and consistent earnings beats, though valuation metrics like P/E of 9.65 suggest potential undervaluation. Recent news highlights institutional interest and positive momentum coverage from financial media.
The stock presents a value opportunity with attractive valuation ratios and solid earnings growth, but faces near-term technical headwinds and mixed analyst sentiment. Key risks include market volatility and execution challenges in the competitive banking sector, while institutional accumulation and strong South Korean market performance provide supportive tailwinds.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
